October 2019

Contents

Editorial

• HTB 18 October 2019 online

Conference reports

• IDWeek (2019), 2–6 October 2019, Washington DC

• HIV suppression and safety with ibalizumab at 48 weeks in expanded access

• Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study

• Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available

• Switching from TDF to TAF linked to higher BMI and cardio risk

• Possible higher diabetes risk with raltegravir or PIs than NNRTIs

• Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives

• Over half of mostly black US HIV group has NAFLD – and many have NASH

• People taking more medications and women have higher fall risk in older HIV group

• No link between raltegravir and adverse birth outcomes in analysis in 2550 women

• PrEP linked to lower HIV incidence in US, independent of TasP

Antiretrovirals

• Dual dolutegravir/lamivudine submitted to US FDA as switch option

Treatment access

• UK contributes £1.4 billion towards Global Fund for 2020 to 2022

• Global Fund raises US$14 billion for 2020 to 2022

Guidelines

• NHS England best practice in HIV prescribing and multidisciplinary teams

HIV prevention and transmission

• US approves F/TAF for PrEP (Descovy): indication excludes risk from receptive vaginal sex

Basic science and immunology

• Science journal retracts article linking CCR5 deletion to reduced life expectancy

PDFs

• 18 October 2019 vol 20 no 12